Matinas BioPharma Holdings IncNYSE American:MTNB
- LAST PRICE0.1920
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.1890/ 1
- Ask / Lots0.1919/ 1
- Open / Previous Close0.0000 / 0.1920
- Day Range---
- 52 Week Range
- Volume5,919
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MTNB |
|---|---|---|
| 09:32 ET | 9578 | 0.2 |
| 09:38 ET | 500 | 0.2037 |
| 09:41 ET | 400 | 0.2 |
| 09:43 ET | 3400 | 0.1999 |
| 09:48 ET | 9150 | 0.2013 |
| 09:50 ET | 1000 | 0.1999 |
| 09:52 ET | 80000 | 0.2 |
| 09:59 ET | 6200 | 0.2 |
| 10:12 ET | 100 | 0.2032 |
| 10:14 ET | 20000 | 0.20135 |
| 10:19 ET | 4001 | 0.2013 |
| 10:21 ET | 100 | 0.2013 |
| 10:28 ET | 3189 | 0.2005 |
| 10:30 ET | 53200 | 0.2 |
| 10:32 ET | 17957 | 0.1999 |
| 10:33 ET | 21200 | 0.199 |
| 10:35 ET | 100 | 0.199 |
| 10:37 ET | 1218 | 0.1995 |
| 10:44 ET | 100 | 0.1999 |
| 10:48 ET | 260538 | 0.199 |
| 10:53 ET | 6557 | 0.19945 |
| 10:55 ET | 4584 | 0.199 |
| 10:57 ET | 5800 | 0.199 |
| 11:02 ET | 3368 | 0.1995 |
| 11:04 ET | 1100 | 0.19895 |
| 11:06 ET | 100 | 0.1989 |
| 11:13 ET | 1000 | 0.199 |
| 11:18 ET | 32505 | 0.1905 |
| 11:20 ET | 30667 | 0.19 |
| 11:22 ET | 100 | 0.195 |
| 11:24 ET | 300 | 0.1925 |
| 11:33 ET | 11300 | 0.193 |
| 11:36 ET | 326 | 0.193 |
| 11:38 ET | 4134 | 0.1936 |
| 11:40 ET | 3300 | 0.19365 |
| 11:45 ET | 4000 | 0.1937 |
| 11:47 ET | 6070 | 0.1936 |
| 11:49 ET | 19074 | 0.193 |
| 11:51 ET | 1000 | 0.193 |
| 11:54 ET | 5230 | 0.193499 |
| 12:02 ET | 10639 | 0.1978 |
| 12:09 ET | 85913 | 0.1975 |
| 12:12 ET | 240 | 0.1936 |
| 12:16 ET | 666 | 0.1978 |
| 12:21 ET | 1000 | 0.1956 |
| 12:23 ET | 100 | 0.1966 |
| 12:32 ET | 1300 | 0.1976 |
| 12:34 ET | 5120 | 0.1956 |
| 12:36 ET | 5000 | 0.1955 |
| 12:39 ET | 5000 | 0.1955 |
| 12:43 ET | 200 | 0.195601 |
| 12:48 ET | 3556 | 0.1957 |
| 12:56 ET | 20300 | 0.1959 |
| 12:59 ET | 1855 | 0.1935 |
| 01:01 ET | 4100 | 0.1959 |
| 01:10 ET | 78244 | 0.194 |
| 01:12 ET | 500 | 0.1958 |
| 01:15 ET | 1800 | 0.1958 |
| 01:24 ET | 26278 | 0.1955 |
| 01:33 ET | 600 | 0.195 |
| 01:39 ET | 200 | 0.19455 |
| 01:42 ET | 200 | 0.1945 |
| 01:44 ET | 4000 | 0.1937 |
| 01:46 ET | 200 | 0.1928 |
| 01:48 ET | 100 | 0.1928 |
| 01:50 ET | 200 | 0.1928 |
| 01:51 ET | 100 | 0.1928 |
| 01:55 ET | 200 | 0.193 |
| 01:57 ET | 100 | 0.193 |
| 02:00 ET | 200 | 0.1931 |
| 02:04 ET | 100 | 0.1931 |
| 02:06 ET | 200 | 0.1931 |
| 02:08 ET | 100 | 0.1931 |
| 02:09 ET | 100 | 0.1931 |
| 02:11 ET | 200 | 0.1931 |
| 02:15 ET | 100 | 0.1931 |
| 02:18 ET | 200 | 0.19425 |
| 02:20 ET | 100 | 0.1931 |
| 02:27 ET | 100 | 0.1931 |
| 02:29 ET | 600 | 0.193 |
| 02:33 ET | 700 | 0.1931 |
| 02:36 ET | 1200 | 0.194 |
| 02:38 ET | 100 | 0.1931 |
| 02:42 ET | 100 | 0.1931 |
| 02:44 ET | 520 | 0.194999 |
| 02:45 ET | 100 | 0.1931 |
| 02:47 ET | 500 | 0.194 |
| 02:49 ET | 100 | 0.1931 |
| 02:51 ET | 49935 | 0.1906 |
| 02:56 ET | 100 | 0.1906 |
| 02:58 ET | 200 | 0.1911 |
| 03:00 ET | 300 | 0.191 |
| 03:02 ET | 100 | 0.191 |
| 03:03 ET | 200 | 0.191 |
| 03:05 ET | 200 | 0.191 |
| 03:07 ET | 1000 | 0.1932 |
| 03:09 ET | 100 | 0.191 |
| 03:12 ET | 100 | 0.191 |
| 03:14 ET | 200 | 0.191 |
| 03:18 ET | 100 | 0.192 |
| 03:20 ET | 100 | 0.192 |
| 03:21 ET | 100 | 0.192 |
| 03:25 ET | 8096 | 0.192 |
| 03:27 ET | 100 | 0.192 |
| 03:32 ET | 100 | 0.192 |
| 03:34 ET | 100 | 0.192 |
| 03:36 ET | 100 | 0.192 |
| 03:38 ET | 100 | 0.192 |
| 03:39 ET | 200 | 0.192 |
| 03:41 ET | 8153 | 0.191 |
| 03:43 ET | 100 | 0.191 |
| 03:45 ET | 100 | 0.191 |
| 03:48 ET | 6100 | 0.191 |
| 03:50 ET | 1195 | 0.192 |
| 03:52 ET | 1041 | 0.1936 |
| 03:54 ET | 1900 | 0.192 |
| 03:56 ET | 20689 | 0.1936 |
| 03:57 ET | 1100 | 0.1901 |
| 03:59 ET | 8291 | 0.192 |
Apr 3, 2024
Matinas BioPharma Prices $10 Million Registered Direct Offering, from 8:30AM ET on Wednesday Apr 03, 2024 by Dow Jones
8:30AM ET on Wednesday Apr 03, 2024 by Dow Jones
Mar 27, 2024
Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update, from 4:05PM ET on Wednesday Mar 27, 2024 by Dow Jones
4:05PM ET on Wednesday Mar 27, 2024 by Dow Jones
Mar 25, 2024
Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation, from 8:00AM ET on Monday Mar 25, 2024 by Dow Jones
8:00AM ET on Monday Mar 25, 2024 by Dow Jones
Mar 22, 2024
Three Patients with Invasive Fusarium Infection in Matinas BioPharma's Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response, from 9:15AM ET on Friday Mar 22, 2024 by Dow Jones
9:15AM ET on Friday Mar 22, 2024 by Dow JonesMatinas BioPharma Regains Compliance with NYSE American Continued Listing Standards, from 6:30AM ET on Friday Mar 22, 2024 by Dow Jones
6:30AM ET on Friday Mar 22, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Matinas BioPharma Holdings Inc | 48.2M | -1.8x | --- |
VolitionRX Ltd | 48.8M | -1.2x | --- |
Apollomics Inc | 47.4M | -10.5x | --- |
Clene Inc. | 43.6M | -0.6x | --- |
CalciMedica Inc | 46.6M | -0.2x | --- |
ARCA Biopharma Inc | 46.5M | -8.7x | --- |
Company Information
Matinas BioPharma Holdings, Inc. is a biopharmaceutical company. The Company is focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology (LNC Platform). Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. MAT2203 is now positioned for a single, Phase III registration trial (the ORALTO trial) in support of a New Drug Application (NDA) for the treatment of invasive aspergillosis in patients with limited treatment options. It is expanding the utilization of the LNC Platform with small molecules and small oligonucleotides outside of infectious disease, targeting inflammation and oncology. It is also investigating a variety of LNC formulations of two small oligonucleotides designed to target inflammatory cytokines IL-17A and TNFα.
Contact Information
- Headquarters
- Suite 302, 1545 Route 206 SouthBEDMINSTER, NJ, United States 07921
- Phone
- 908-443-1860
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Eric Ende
- President, Chief Executive Officer, Director
- Jerome Jabbour
- Chief Financial Officer
- Keith Kucinski
- Chief Technology Officer
- Hui Liu
- Chief Medical Officer
- James Ferguson
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $48.2M |
|---|---|
Revenue (TTM) | $1.1M |
Shares Outstanding | 250.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.62 |
EPS | $-0.11 |
Book Value | $0.09 |
P/E Ratio | -1.8x |
Price/Sales (TTM) | 43.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -2,124.27% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
